section name header

Indications ⬇

REMS


Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

GI: diarrhea, abdominal distention, abdominal pain, flatulence, gastrointestinal reflux, vomiting

Neuro: fatigue

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Irritable Bowel Syndrome with Constipation

Chronic Idiopathic Constipation

Functional Constipation

US Brand Names ⬆ ⬇

Linzess

Action ⬆ ⬇

  • Locally increases levels of cyclic guanosine monophosphate (cGMP); accelerates transit time, increases intestinal fluid and decreases pain sensation.
Therapeutic effects:
  • Increased frequency of bowel movements with decreased pain associated with IBS-C, CIC, or functional constipation.

Classifications ⬆ ⬇

Therapeutic Classification: anti irritable bowel syndrome agents

Pharmacologic Classification: guanylate cyclase-C agonists

Pharmacokinetics ⬆ ⬇

Absorption: Minimally absorbed, action is primarily local.

Distribution: Stays within the GI tract with minimal distribution.

Metabolism/Excretion: Converted to its principal active metabolite within the GI tract; subsequently locally degraded to smaller peptides and amino acids; 3–5% found in stool, mostly as the active metabolite.

Half-Life: Unknown.

Canadian Brand Names ⬆ ⬇

Constella

Time/Action Profile ⬆ ⬇

(improvement in GI symptoms)

ROUTEONSETPEAKDURATION
POunknown6–9 wk1 wk‡

‡Following discontinuation.



Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆

lin-a-KLOE-tide